文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌高剂量率近距离治疗单药治疗:随机II期试验的晚期毒性与患者报告结局

Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial.
PubMed 文献 · Radiother Oncol · 2021-01-04

这项随机II期试验纳入170例NCCN低危或中危前列腺癌患者,比较单次19 Gy与两次13.5 Gy(间隔一周)高剂量率近距离治疗单药方案的晚期毒性和健康相关生活质量。中位随访63个月,单次组≥2级泌尿生殖毒性5年累积发生率62%、胃肠道12%,两次组分别为47%和9%;单次组4年和5年泌尿生活质量较基线下降,两次组第一年后无显著差异,两组性生活质量各时间点均显著下降。

要点

  • 单次19 Gy组≥2级泌尿生殖毒性5年累积发生率62%,两次13.5 Gy组为47%。
  • 单次组4年和5年泌尿生活质量较基线下降,两次组第一年后无显著差异。
  • 两组性生活质量各时间点均显著下降,肠道生活质量无变化。

核心结论

  • 高剂量率近距离治疗单药治疗耐受良好,对健康相关生活质量影响较小。

研究设计与样本

  • 随机II期临床试验纳入170例NCCN低危或中危前列腺癌患者,随机接受单次19 Gy或两次13.5 Gy(间隔一周)高剂量率近距离治疗单药治疗。
  • 毒性采用CTCAE v4.0评估,生活质量采用EPIC量表评估,中位随访63个月。

主要发现

  • 单次组≥2级泌尿生殖毒性和胃肠道毒性5年累积发生率分别为62%和12%,两次组分别为47%和9%。
  • 3级泌尿生殖毒性仅见于单次组,累积发生率为2%。
  • ≥2级泌尿生殖毒性5年患病率单次组为29%、两次组为21%,≥2级胃肠道毒性分别为1%和2%。
  • 第一年后两次组平均泌尿生活质量较基线无显著差异,单次组在4年和5年出现下降。
  • 两组性生活质量各时间点均显著下降,肠道领域无变化。

临床怎么用

  • 两次13.5 Gy方案在晚期泌尿生殖毒性和泌尿生活质量方面优于单次19 Gy方案。
  • 两种方案均需关注性生活质量下降,单次方案还需警惕3级泌尿生殖毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Long-term toxicity of high dose-rate brachytherapy as monotherapy for prostate cancer is not well defined. We report late toxicity and health related quality of life (HRQOL) changes from a randomized phase II clinical trial of two different fractionation schemes. MATERIALS AND METHODS: Eligible patients had NCCN low or intermediate risk prostate cancer. 170 patients were randomized to receive either a single 19 Gy or two-fractions of 13.5 Gy one week apart. Toxicity was measured using Common Terminology for Adverse Events (CTCAE) v4.0, and HRQOL was measured using the Expanded Prostate Index Composite (EPIC). RESULTS: Median follow-up was 63 months. The 5-year cumulative incidence of Grade 2 or higher genitourinary (GU) and gastrointestinal (GI) toxicity was 62% and 12% in the single-fraction arm, and 47% and 9% in the two-fraction arm, respectively. Grade 3 GU toxicity was only seen in the single fraction arm with a cumulative incidence of 2%. The 5-year prevalence of Grade 2 GU toxicity was 29% and 21%, in the single- and two-fraction arms, respectively, with Grade 2 GI toxicity of 1% and 2%. Beyond the first year, no significant differences in mean urinary HRQOL were seen compared to baseline in the two-fraction arm, in contrast to the single-fraction arm where a decline in urinary HRQOL was seen at 4 and 5 years. Sexual HRQOL was significantly reduced in both treatment arms at all timepoints, with no changes in the bowel domain. CONCLUSIONS: HDR monotherapy is well tolerated with minimal impact on HRQOL.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Corkum M, Loblaw A, Hasan Y, et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiother Oncol. 2021. PMID: 33359269. doi:10.1016/j.radonc.2020.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。